Roivant officer Eric Venker proposes $7.32M share sale

The proposed sale is to occur under a Rule 10b5-1 trading plan adopted March 28, 2025.

Rhea-AI Filing Summary

Roivant Sciences Ltd. officer Eric Venker reported a proposed sale of 200,000 common shares through Rockefeller Financial LLC, with an aggregate market value of $7,323,556.00. The stated sale date is September 30, 2026, and the shares are to be sold under a Rule 10b5-1 trading plan adopted March 28, 2025.

Key Figures

Proposed sale: 200,000 common shares Aggregate market value: $7,323,556.00 Shares sold: 200,000 shares +5 more

8 metrics

Proposed sale 200,000 common shares Eric Venker; September 30, 2026

Aggregate market value $7,323,556.00 Proposed sale

Shares sold 200,000 shares July 27, 2026; prior three months

Reported sale amount $6,989,924.05 July 27, 2026; prior three months

Shares sold 13,909 shares August 20, 2026; prior three months

Reported sale amount $512,407.56 August 20, 2026; prior three months

Shares sold 200,000 shares August 28, 2026; prior three months

Reported sale amount $7,147,087.91 August 28, 2026; prior three months

Key Terms

Rule 10b5-1 trading plan, Rule 144, Options Exercise

3 terms

Rule 10b5-1 trading plan regulatory

"sold pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Rule 144 regulatory

"the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Options Exercise financial

"Options Exercise - Grant Date 04/20/2022"

Exercising an option is the act of using a contract that gives you the right to buy or sell a specific stock at a set price. For investors, the decision to exercise matters because it turns a paper right into an actual trade — it can create immediate profit or loss, change how many shares are outstanding (which can dilute ownership), affect cash the investor must pay or receive, and trigger tax consequences, much like deciding to redeem a coupon for a fixed-price purchase.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares did Eric Venker report for sale?

The reported proposed sale is 200,000 common shares, with an aggregate market value of $7,323,556.00, through Rockefeller Financial LLC. The stated sale date is September 30, 2026, under a Rule 10b5-1 trading plan adopted March 28, 2025.

What prior ROIV sales did Eric Venker report?

For the prior three months, the reported sales were 200,000 shares with a reported amount of $6,989,924.05 on July 27, 2026; 13,909 shares with a reported amount of $512,407.56 on August 20, 2026; and 200,000 shares with a reported amount of $7,147,087.91 on August 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 04:22 PM Accepted by SEC EDGAR 09/30/2026 - 04:21 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	200000	7323556.00	722323015	09/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	09/30/2026	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.			200000	09/30/2026	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway, London X0 SW1H0DB	Common Shares	07/27/2026	200000	6989924.05
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway, London X0 SW1H0DB	Common Shares	08/20/2026	13909	512407.56
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	08/28/2026	200000	7147087.91

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/28/2025.
Date of Notice	09/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/28/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Venker Eric
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)